Zoetis Inc (ZTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zoetis Inc (ZTS) has a cash flow conversion efficiency ratio of 0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($938.00 Million) by net assets ($5.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZTS market cap for the company's overall valuation and market capitalisation.
Zoetis Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Zoetis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zoetis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zoetis Inc ranked by their cash flow conversion efficiency. Explore Zoetis Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ABN Amro Group NV
AS:ABN
|
0.010x |
|
BeiGene, Ltd.
NASDAQ:ONC
|
0.042x |
|
Accton Technology Corp
TW:2345
|
0.377x |
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-B
|
0.077x |
|
EQT Corporation
NYSE:EQT
|
0.036x |
|
CHINA PAC.IN.GR.GDR/5 YC1
F:75CB
|
N/A |
|
Vulcan Materials Company
NYSE:VMC
|
0.040x |
|
Hyundai Heavy Industries Co Ltd
KO:329180
|
0.175x |
Annual Cash Flow Conversion Efficiency for Zoetis Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Zoetis Inc from 2010 to 2024. View Zoetis Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.77 Billion | $2.95 Billion | 0.619x | +31.31% |
| 2023-12-31 | $4.99 Billion | $2.35 Billion | 0.471x | +8.57% |
| 2022-12-31 | $4.40 Billion | $1.91 Billion | 0.434x | -10.83% |
| 2021-12-31 | $4.54 Billion | $2.21 Billion | 0.487x | -13.57% |
| 2020-12-31 | $3.77 Billion | $2.13 Billion | 0.563x | -14.99% |
| 2019-12-31 | $2.71 Billion | $1.79 Billion | 0.663x | -19.09% |
| 2018-12-31 | $2.19 Billion | $1.79 Billion | 0.819x | +8.70% |
| 2017-12-31 | $1.79 Billion | $1.35 Billion | 0.754x | +58.44% |
| 2016-12-31 | $1.50 Billion | $713.00 Million | 0.476x | -21.85% |
| 2015-12-31 | $1.09 Billion | $664.00 Million | 0.609x | +29.99% |
| 2014-12-31 | $1.34 Billion | $626.00 Million | 0.468x | -33.86% |
| 2013-12-31 | $962.00 Million | $681.00 Million | 0.708x | +530.09% |
| 2012-12-31 | $4.04 Billion | $454.00 Million | 0.112x | -15.55% |
| 2011-12-31 | $3.74 Billion | $497.00 Million | 0.133x | +75.14% |
| 2010-12-31 | $3.34 Billion | $254.00 Million | 0.076x | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more